SMZ/TMP
|
|
|
- CAS-Nr.
- 8064-90-2
- Englisch Name:
- SMZ/TMP
- Synonyma:
- Trimethoprim-Sulfamethoxazole;TMP-SMX;SMZ/TMP;Septrim;Chemitrim;Trimforte;Trimethoprimsulfa;Co-Trimoxazole (CTX), 95%;Sulfamethoxazole/Trimethoprim;TRIMETHOPRIM/SULPHAMETHOXAZOLE
- CBNumber:
- CB01105579
- Summenformel:
- C24H29N7O6S
- Molgewicht:
- 543.6
- MOL-Datei:
- 8064-90-2.mol
|
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Kennzeichnung gef?hrlicher |
Xi |
|
|
| R-S?tze: |
36/37/38-43 |
|
|
| S-S?tze: |
26-36/37 |
|
|
| WGK Germany |
3 |
|
|
| RTECS-Nr. |
UV8240000 |
|
|
| Speicherklasse |
12 - Non Combustible Liquids |
|
|
| Hazard Classifications |
Aquatic Chronic 3
Repr. 2 |
|
|
| Giftige Stoffe Daten |
8064-90-2(Hazardous Substances Data) |
|
|
| Toxizit?t |
LD50 orally in mice: 5513 mg/kg (Yamamoto) |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H317 |
Kann allergische Hautreaktionen verursachen. |
Sensibilisierung der Haut |
Kategorie 1A |
Warnung |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
SMZ/TMP Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Cotrimoxazole is an antibiotic. Pseudomonas aeruginosa has a drug resistant rate of 66% in the years 2010-2013.
Weltgesundheitsorganisation (WHO)
The combination of sulfamethoxazole and trimethoprim (5:1) was
introduced in 1971 for the treatment of a wide variety of bacterial infections. Its use
has been associated with severe sensitivity reactions, many of which have been
attributed to the sulphonamide component. Elderly people seem to be more
vulnerable. The World Health Organization has no information further to the above
concerning restrictive action taken on this combination.
Nebenwirkungen
Trimethoprim/sulfamethoxazole on a daily basis has a rapid onset of action
but has rare associated side effects of bone marrow suppression and toxic
epidermal necrolysis (TEN).
Nausea, vomiting, and anorexia are generally dose related.
Hypersensitivity reactions (including Stevens-Johnson syndrome and hematologic
reactions) occur in <5% of patients.
SMZ/TMP Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
SMZ/TMP Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 22)Lieferanten
8064-90-2()Verwandte Suche:
- SMZ/TMP
- Sulfamethoxazole/Trimethoprim
- Trimethoprim-Sulfamethoxazole Combination
- TRIMETHOPRIM/SULPHAMETHOXAZOLE
- Chemitrim
- Septrim
- Cotrimoxazole, Ready Made Solution
- TMP-SMX
- Co-Trimoxazole (CTX), 95%
- Trimethoprimsulfa
- Trimforte
- 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine mixture with 4-amino-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide
- Cotrimoxazole (Trimethoprim/sulfamethoxazole 1:19)
- Trimethoprim-Sulfamethoxazole
- 8064-90-2
